Karyopharm reports Q2 revenue of $33.4 million, reaffirms 2026 guidance
Karyopharm Therapeutics reported second-quarter revenue of $33.4 million, down from $37.9 million a year earlier, and reaffirmed 2026 revenue guidance of $130 million to $150 million.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.